Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.13.
Protalix BioTherapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.12.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 33.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Protalix BioTherapeutics's Operating Cash Flow per Share or its related term are showing as below:
PLX'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -144 Med: 17.55 Max: 73.9
Current: 33.3
During the past 13 years, Protalix BioTherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.90% per year. The lowest was -144.00% per year. And the median was 17.55% per year.
PLX's 3-Year OCF Growth Rate is ranked better than 70.61% of 1133
companies
in the Biotechnology industry
Industry Median: 17
vs PLX: 33.30
Protalix BioTherapeutics Operating Cash Flow per Share Related Terms
Protalix BioTherapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Protalix BioTherapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Operating Cash Flow per Share Chart
PLX vs CUE, ORMP, ARMP: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.12 mean?
Protalix BioTherapeutics (PLX) has a Operating Cash Flow per Share of $0.12 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #333 out of 1133 companies in the Biotechnology industry, placing it in the top 29.4%.
Is Protalix BioTherapeutics' Operating Cash Flow per Share too high?
Protalix BioTherapeutics' current Operating Cash Flow per Share is $0.12. The Biotechnology industry median Operating Cash Flow per Share is 17.00. Protalix BioTherapeutics' value of $0.12 is 99.3% below this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #333 out of 1133 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Operating Cash Flow per Share compare to CUE and ORMP?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #333 out of 1133 companies for Operating Cash Flow per Share. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median Operating Cash Flow per Share is 17.00. Protalix BioTherapeutics' value of $0.12 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current Operating Cash Flow per Share of $0.12 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Operating Cash Flow per Share is $0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.20, compared to a current price of $2.68 — trading 21.8% above its estimated fair value. The current Operating Cash Flow per Share is $0.12 and 99.3% below the Biotechnology industry median of 17.00. Protalix BioTherapeutics' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Operating Cash Flow per Share is $0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.68 is trading 21.8% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Modestly Overvalued.
Key valuation signals for PLX:
Operating Cash Flow per Share: $0.12
GF Value™: $2.20 vs. price of $2.68 (21.8% above fair value)
Industry Position: 99.3% below the Biotechnology median (#333 of 1133)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
60GF Score
Get the complete analysis for PLX
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
